{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"* Evaluate tumor specific responses in blood and bone marrow\n* Examine T cell responses to DC-pulsed myeloma cell lines\n* Examine induction of novel antibody responses","groups":[{"description":"Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4.\n\nActivated marrow infiltrating lymphocytes: Administered on Days 3 and 4.\n\nCyclophosphamide: Administered at 2.5 g/m\\^2.\n\nFilgrastim: Administered post cyclophosphamide daily until leukapheresis.\n\nLeukapheresis: Performed approximately 12 days post cyclophosphamide. Exact date depends on peripheral blood CD34+ cell counts.\n\nMelphalan: 100 mg/m\\^2/day given on Days -2 and -1.\n\nAutologous stem cell transplant: Infused on Day 0.","id":"OG000","title":"ASCT + MILs"},{"description":"Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4. The allogeneic myeloma vaccine will be administered on Days 21, 60, 180, and 300.\n\nActivated marrow infiltrating lymphocytes: Administered on Days 3 and 4.\n\nAllogeneic Myeloma Vaccine: Allogeneic granulocyte macrophage colony-stimulating factor (GM-CSF)-based myeloma cellular vaccine. Administered on Days 21, 60, 180, and 300.\n\nCyclophosphamide: Administered at 2.5 g/m\\^2.\n\nFilgrastim: Administered post cyclophosphamide daily until leukapheresis.\n\nLeukapheresis: Performed approximately 12 days post cyclophosphamide. Exact date depends on peripheral blood CD34+ cell counts.\n\nMelphalan: 100 mg/m\\^2/day given on Days -2","id":"OG001","title":"ASCT + MILs + Vaccine"}],"populationDescription":"This measure was not assessed. Data was not collected.","reportingStatus":"POSTED","timeFrame":"Days 60, 180, and 360","title":"Anti-tumor Immune Response","type":"SECONDARY"}